[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Bright Minds Biosciences Inc (DRUG.CN)

Bright Minds Biosciences Inc (DRUG.CN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])

Fundamentals

See More
  • Market Capitalization, $K 1,078,934
  • Shares Outstanding, K 9,812
  • Annual Sales, $ 0 K
  • Annual Income, $ -12,229 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta -9.52
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.50

Price Performance

See More
Period Period Low Period High Performance
1-Month
89.3800 +20.19%
on 06/26/26
110.2700 -2.58%
on 07/17/26
+18.1500 (+20.33%)
since 06/22/26
3-Month
80.4800 +33.49%
on 06/16/26
127.4300 -15.69%
on 05/27/26
-14.7600 (-12.08%)
since 04/22/26
52-Week
37.4700 +186.71%
on 07/23/25
170.0000 -36.81%
on 01/06/26
+71.8300 (+201.77%)
since 07/22/25

Most Recent Stories

More News
Bright Minds Biosciences to Present at Jefferies Global Healthcare Conference

NEW YORK, May 26, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly selective...

DRUG : 75.54 (-2.26%)
DRUG.CN : 105.7500 (-3.83%)
Bright Minds Biosciences to Present at Upcoming Conferences

NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly selective...

DRUG : 75.54 (-2.26%)
DRUG.CN : 105.7500 (-3.83%)
Canadian Securities Exchange Reports January 2026 Performance Figures

Toronto, Ontario--(Newsfile Corp. - February 17, 2026) - The Canadian Securities Exchange ("CSE" or "the Exchange") today announced market statistics for January 2026.January 2026 Operating StatisticsTrading...

ALAR.CN : 0.2250 (unch)
TTC.CN : 0.3500 (unch)
HUNT.CN : 0.0400 (unch)
UG.CN : 0.9500 (-1.04%)
DRUG.CN : 105.7500 (-3.83%)
Upcoming Meeting Dates - February 2, 2026

Toronto, Ontario--(Newsfile Corp. - February 2, 2026) - The following is a list of Upcoming Meeting Dates announced this week for Reporting Issuers in Canada. The data is supplied by Issuing Companies...

ESG.TO : 55.56 (unch)
CAPR.CN : 0.0800 (unch)
OGI.TO : 1.31 (-1.14%)
BTT.VN : 0.035 (unch)
CRCL.CN : 0.1350 (+3.85%)
RGI.VN : 0.010 (unch)
MEK.VN : 0.050 (unch)
MARY.CN : 0.0200 (unch)
SFI.TO : 0.2700 (unch)
ENEV.VN : 0.005 (unch)
URZ.VN : 0.140 (-6.67%)
ZONE.VN : 0.010 (unch)
Bright Minds Biosciences Announces Closing of US$175 Million Public Offering

NEW YORK, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“ Bright Minds ” or the “ Company ”) today closed its recently announced public offering...

DRUG : 75.54 (-2.26%)
DRUG.CN : 105.7500 (-3.83%)
Bright Minds Biosciences Announces Pricing of Upsized US$175 Million Public Offering of Common Stock

NEW YORK, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“ Bright Minds ” or the “ Company ”) announces the pricing of its previously announced...

DRUG : 75.54 (-2.26%)
DRUG.CN : 105.7500 (-3.83%)
Bright Minds Biosciences Announces Launch of US$100 Million Public Offering

NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“ Bright Minds ” or the “ Company ”) announces the launch of a public offering of common...

DRUG : 75.54 (-2.26%)
DRUG.CN : 105.7500 (-3.83%)
Bright Minds Biosciences Announces Positive Topline Results from Phase 2 Clinical Trial of BMB-101 in Patients with Absence Seizures and Developmental and Encephalopathic Epilepsies (DEE)

BMB-101 demonstrated significant anti-seizure benefit in both cohorts with favorable safety and tolerability Absence: 73.1% median reduction in the number of absence seizure ≥3s, p = 0.012 DEE: 63.3%...

DRUG : 75.54 (-2.26%)
DRUG.CN : 105.7500 (-3.83%)
Bright Minds to Announce Topline Results for BMB-101 Phase 2 Trial in Absence Seizures and Developmental and Epileptic Encephalopathies on Tuesday, January 6, 2026

– Conference Call and Live Webcast at 8AM ET – NEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (Nasdaq: DRUG) (“Bright Minds” or the “Company”),...

DRUG : 75.54 (-2.26%)
DRUG.CN : 105.7500 (-3.83%)
Bright Minds Biosciences to Present at Piper Sandler 37th Annual Healthcare Conference and 2025 AES Annual Meeting

NEW YORK, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly selective...

DRUG : 75.54 (-2.26%)
DRUG.CN : 105.7500 (-3.83%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders...

See More

Key Turning Points

3rd Resistance Point 113.0933
2nd Resistance Point 111.5267
1st Resistance Point 110.7433
Last Price 105.7500
1st Support Level 108.3933
2nd Support Level 106.8267
3rd Support Level 106.0433

See More

52-Week High 170.0000
Fibonacci 61.8% 119.3735
Last Price 105.7500
Fibonacci 50% 103.7350
Fibonacci 38.2% 88.0965
52-Week Low 37.4700

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.